Vernal Keratoconjunctivitis Market
According to Intent Market Research, the Vernal Keratoconjunctivitis Market is expected to grow from USD 127.3 million in 2024-e at a CAGR of 10.1% to touch USD 227.2 million by 2030. The Vernal Keratoconjunctivitis Market is dominated by key players such as, Allergan (AbbVie Inc.), Novartis International AG, GlaxoSmithKline plc, Pfizer Inc., and Sun Pharmaceutical Industries Ltd..